Silence Therapeutics (SLNCF) Stock Price, News & Analysis

Company Overview

Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.

The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development. Other pipeline candidates include SLN124 for the treatment of iron overload disorders such as beta-thalassemia and myelodysplastic syndromes, as well as preclinical programs targeting oncology and metabolic disease. Silence Therapeutics collaborates with pharmaceutical partners to explore broader applications of its AtuPLEX lipid nanoparticle formulation and ligand-conjugation approaches, seeking to maximize the therapeutic potential of RNA-based interventions.

Headquartered in London, Silence Therapeutics maintains research operations in Germany and the United States to support its global development efforts. The company is led by a management team with extensive experience in RNA biology, drug development and regulatory affairs. Silence Therapeutics is publicly listed on the London Stock Exchange and trades in the United States over the counter under the symbol SLNCF, enabling investors to follow its progress as it advances innovative RNAi therapeutics toward commercialization.

Key Stats

• Today's Range: $1.60 to $1.60
• 50-Day Range: $1.60 to $1.69
• 52-Week Range: $0.50 to $6.75
• Volume: N/A
• Average Volume: 12,621 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SLNCF Stock Analysis - Frequently Asked Questions

How have SLNCF shares performed this year?

Silence Therapeutics' stock was trading at $2.6250 at the start of the year. Since then, SLNCF shares have decreased by 39.0% and is now trading at $1.60.

How do I buy shares of Silence Therapeutics?

Shares of SLNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SLNCF
• CIK: 1479615
• Web: www.silence-therapeutics.com
• Phone: 442034576900
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A